Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Primeiros resultados da Parte B do estudo CheckMate 914 - monoterapia ...
CheckMate 914 Part B: Nivolumab Monotherapy for Localized RCC After ...
ASCO GU 2024: CheckMate 914 Trial – Adjuvant Nivolumab Monotherapy vs ...
CheckMate 914 trial on adjuvant nivolumab | OncoAlert posted on the ...
CheckMate 914: adjuvant nivolumab monotherapy for renal cell carcinoma ...
CheckMate 9DW at ASCO GI 2026: Nivolumab plus ipilimumab vs lenvatinib ...
CheckMate 901 Trial Final Results at ASCO 2025: Nivolumab + Ipilimumab ...
CheckMate 214 Trial Final 9-Year Results at ASCO 2025: Nivolumab Plus ...
CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do ...
CheckMate 274: Adjuvant Treatment With Nivolumab for Patients With MIUC ...
ASCO 2019: CheckMate 214 Post-Hoc Analyses of Nivolumab plus Ipilimumab ...
ESMO 2021: Conditional Survival and 5-Year Follow-Up in CheckMate 214 ...
ASCO 2020: Biomarker Analyses from the Phase III CheckMate 214 Trial of ...
(PDF) Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab ...
ASCO GI中国之声 | CheckMate 649中国亚组3年随访结果：1L纳武利尤单抗+化疗使胃食管癌患者继续获益！ - 肿瘤瞭望
CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First ...
First results from the phase 3 CheckMate 274 trial of adjuvant ...
Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus ...
Figure 2, CheckMate 274 Study Design Schematic - Nivolumab (Opdivo ...
OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients ...
(PDF) Checkmate 274 trial: Is Nivolumab the new standard in adjuvant ...
ASCO GU 2019: CheckMate 214 Trial - Thirty Month Follow-up of First ...
Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus ...
ASCO GU 2021: CheckMate 9KD Arm B Final Analysis: Efficacy and Safety ...
ESMO 2024: Health-Related Quality of Life from the CheckMate 901 Trial ...
ESMO 2022: Adjuvant Nivolumab Plus Ipilimumab vs Placebo for Localized ...
ASCO 2020: A Phase III, Randomized, Placebo-Controlled Trial of ...
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal ...
EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell ...
Exploring Adjuvant Therapies in Renal Cell Carcinoma
(PDF) Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus ...
CCR de alto riesgo localmente avanzado: nivolumab adyuvante no cumplió ...
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of ...
ASCO GU 2024: Adjuvant Nivolumab Monotherapy vs Placebo for Localized ...
SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
A trial of nivolumab with or without ipilimumab after surgery for ...
ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
ASCO GU 2020: Overall Survival and Independent Review of Response in ...
Nivolumab plus ipilimumab versus nivolumab in microsatellite ...
Safety and efficacy of first-line nivolumab plus ipilimumab alternating ...
切除不能進行・再発食道扁平上皮癌に対する1次治療としてのNivolumab＋IpilimumabまたはNivolumab＋化学療法vs.化学 ...
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of ...
Kidney Cancer | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab ...
(PDF) Nivolumab plus ipilimumab versus sunitinib for first-line ...
腎細胞がん、ニボルマブ＋イピリムマブによるアジュバント療法のサブグループ解析（CheckMate 914）／ASCO2023｜医師向け医療 ...
ASCO 2019: Safety and Efficacy of Nivolumab plus Ipilimumab in Patients ...
Four-year clinical update and treatment switching-adjusted outcomes ...
First-line nivolumab plus ipilimumab combined with two cycles of ...
盛锡楠教授：转移性肾癌BIONIKK、CheckMate 9ER研究——免疫和靶向，并排走还是前后走丨瞭望FM·ESMO特辑_治疗
From neoadjuvant to second-line therapeutic options for RCC patients ...
Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more ...
ASCO GU 2024: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in ...
ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal ...
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of ...
EAU 2025: State-of-the-Art Lecture: Role of Perioperative Neoadjuvant ...
Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary ...
2025版EAU肾细胞癌（RCC）指南更新，纳入特瑞普利单抗和贝组替凡等多种新型药物研究结果
Patient-reported outcomes of patients with advanced renal cell ...
SIU 2021: New Systemic Therapies in Advanced Renal Cell Carcinoma
ASCO GU 2024：Nivolumab/Ipilimumab在未经治疗的晚期或转移性RCC患者中显示出显著的生存获益（CheckMate ...
Adjuvant immunotherapy does not improve DFS in renal cancer
Where Do We Stand With Advanced and Metastatic RCC? | GU Oncology Now
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced ...
ASCO GU 2025: Adjuvant Therapy in Renal Cell Cancer: A Practical Guide
Evaluation of Two Dosing Regimens for Nivolumab in Combination With ...
(PDF) Efficacy of Nivolumab for Head and Neck Cancer Patients with ...
Nierenzellkarzinom: Paradigmenwechsel und mysteriöse Mikrobiome ...
ASCO 2025: An Integrative Analysis of Circulating and Tumor ...
Safety and efficacy of nivolumab plus ipilimumab in patients with ...
The Treatment of Metastatic Renal Cell Carcinoma: An Update - GIN
.jpg)
02574-0/asset/44913851-e080-49e4-a451-eb27da4ff784/main.assets/gr1_lrg.jpg)
02848-4/asset/d736f3f4-9315-48ed-b98c-790c6566d173/main.assets/gr2_lrg.jpg)
02848-4/asset/eea0e057-084b-4e9a-bb28-c5594d5b26e1/main.assets/gr3_lrg.jpg)
30641-0/asset/58152fdc-1b05-44e3-8d75-6c64df3d642f/main.assets/gr1.gif)
